"Dartmouth Health, New Hampshire's only academic health system and the state's largest private employer, serves patients across northern New England. Dartmouth Health provides access to more than 2,000 providers in almost every area of medicine, delivering care at its flagship hospital, Dartmouth Hitchcock Medical Center (DHMC) in Lebanon, NH, as well as across its wide network of hospitals, clinics and care facilities. DHMC is consistently named the #1 hospital in New Hampshire by U.S. News & World Report, and recognized for high performance in numerous clinical specialties and procedures."

During the past decade, Dartmouth - Hitchcock Concord conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 4 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Dartmouth - Hitchcock Concord" #1 collaborator was "National Cancer Institute (NCI)" with 6 trials as a collaborator, "NRG Oncology" with 5 trials as a collaborator, "Cancer and Leukemia Group B" with 1 trials as a collaborator, "European Organisation for Research and Treatment of Cancer - EORTC" with 1 trials as a collaborator and "NCIC Clinical Trials Group" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Dartmouth - Hitchcock Concord" are "Brain and Central Nervous System Tumors" (2 trials), "Prostate Cancer" (2 trials), "Breast Cancer" (1 trials) and "Head and Neck Cancer" (1 trials). Many other conditions were trialed in "Dartmouth - Hitchcock Concord" in a lesser frequency.

Most popular intervention types in "Dartmouth - Hitchcock Concord" are "Radiation" (6 trials), "Drug" (5 trials) and "Procedure" (2 trials). Other intervention types were less common.

The name of intervention was led by "adjuvant therapy" (2 trials), "radiation therapy" (2 trials), "100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle" (1 trials), "75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle" (1 trials) and "Accelerated Fractionation by Concomitant Boost" (1 trials). Other intervention names were less common.

The vast majority of trials in "Dartmouth - Hitchcock Concord" are 3 trials for "All" genders, 2 trials for "Male" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Dartmouth - Hitchcock Concord". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 6 completed trials in Dartmouth - Hitchcock Concord, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Dartmouth - Hitchcock Concord, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".